Fresenius Group Overview

  • FY/18 & Q4/18 Results

    Fresenius reports 15th consecutive record yearSignificant investments into medium-term growth in FY/18 and FY/19

New Developments

Financial Highlights

Sales

€ 33530 m

+6%1, 2

FY/17: €32,841 m2

Dividende3

€ 0.80

+7%

FY/17: €0.75

EBIT4

€ 4561 m

-1%1

FY/17: €4,746 m

Employees

276,750

Dec. 31, 2017: 273,249

Net Income4

€ 1871 m

+7%1

FY/17: €1,804 m

Earnings per Share4

€ 3.37

+6%1

FY/17: €3.26

1 In constant currency
2 Adjusted for IFRS 15 adoption and divestitures of Care Coordination activities
3 FY/18 Proposal
4 Before special items and after adjustments

CEO message

“2018 was not an easy year, and yet it was another successful one for Fresenius. We have further developed and enhanced our medical offering, while once again increasing both sales and earnings. 2019 will be a year of investment in growth areas such as home dialysis, biosimilars and new hospital services and therapies. Our goal is to provide even better treatment for even more patients as the basis for continued, strong growth – which is also reflected in our healthy mid-term growth targets.”

 

 


Stephan Sturm, Chairman of the Management Board 

  • Business Segments

    • 7% comparable sales growth in constant currency in Q4/18
    • 9% comparable net income increase in constant currency in Q4/18
    • Attractive share buyback program for 2019 and 2020
    • Outlook for FY/19 (in constant currency): 3% to 7% adjusted sales growth and adjusted net income development  in range of -2% to +2% expected

     

  • Business Segments

    • 7% organic sales growth and 10% EBIT growth in constant currency (excl. biosimilars expenses) in FY/18
    • Operating cash flow at all-time high
    • FY/19 outlook: 3 to 6% organic sales growth  and 3 to 6% EBIT  growth in constant currency expected

  • Business Segments

    • 4% organic sales growth in Q4/18
    • DRG catalogue effects and preparatory initiatives for regulatory changes continue to weigh on Helios Germany
    • Helios Spain with dynamic growth
    • FY/19 outlook : 2% to 5% organic sales growth and EBIT decline of -5% to -2% expected

     

  • Business Segments

    • Excellent organic sales growth of 16% in FY/18
    • Order intake at all-time high - strong foundation for future growth
    • FY/19 outlook: ~10% organic sales growth and 15% to 20% EBIT growth  expected

     

     

     

News

All Financial Reports